# Zhengbo Song

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zhengbo-song/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,190 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 35 |
| i10-index | 113 |
| Last Known Institution | Chinese Academy of Sciences |
| OpenAlex ID | https://openalex.org/A5066879163 |
| ORCID iD | 0000-0002-4817-7775 |
| Works | 287 |

## Researcher papers

- [Extracellular vesicles: Natural liver‐accumulating drug delivery vehicles for the treatment of liver diseases](https://scholariq.org/papers/extracellular-vesicles-natural-liver-accumulating-drug-delivery-vehicles-for-the/)
- [Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC](https://scholariq.org/papers/identification-of-deleterious-i-notch-i-mutation-as-novel-predictor-to/)
- [Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation](https://scholariq.org/papers/ursodeoxycholic-acid-reduces-antitumor-immunosuppression-by-inducing-chip/)
- [Large-scale targeted metabolomics method for metabolite profiling of human samples](https://scholariq.org/papers/large-scale-targeted-metabolomics-method-for-metabolite-profiling-of-human/)
- [A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance](https://scholariq.org/papers/a-comparison-of-ddpcr-and-arms-for-detecting-egfr-t790m-status-in-ctdna-from/)
- [D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results](https://scholariq.org/papers/d-1553-garsorasib-a-potent-and-selective-inhibitor-of-krasg12c-in-patients-with/)
- [Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients](https://scholariq.org/papers/correlation-of-egfr-mutation-and-predominant-histologic-subtype-according-to-the/)
- [Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring &lt;em&gt;EGFR&lt;/em&gt; exon 20 mutations](https://scholariq.org/papers/clinical-efficacy-of-first-generation-egfr-tkis-in-patients-with-advanced-non/)
- [Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma](https://scholariq.org/papers/programmed-death-ligand-1-expression-associated-with-molecular-characteristics/)
- [Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—Based on a hospital study in China](https://scholariq.org/papers/prognostic-value-of-the-iaslc-ats-ers-classification-in-stage-i-lung/)
- [Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study](https://scholariq.org/papers/genomic-alterations-and-clinical-outcomes-in-patients-with-lung-adenocarcinoma/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Chinese Academy of Sciences](https://scholariq.org/institutions/chinese-academy-of-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.